Abstract
Objectives: To study the effect of sulfotanshinone sodium (SS) injection in the treatment of non-ischemic retinal vein occlusion (RVO). Methods: Sixty-two RVO patients treated in our hospital between Jan. 2013 and Oct. 2014 were randomly divided into Control Group (30 patients; Bendazol tablets) and Treatment Group (32 patients, Bendazol tablets + SS injections), each with a follow-up period of 6 months. Statistical analysis was then performed on changes in visual acuity, central retinal thickness (CRT) and retinal circulation time (RCT) before and after the treatment. Results: After treatment, both Control Group and Treatment Group witnessed an improvement on visual acuity (Control Group: t = 2.103, p = 0.044; Treatment Group: t = 8.021, p = 0.000). Visual acuity could be greatly improved in Treatment Group when compared with Control Group, with significant differences (p < 0.01). Macular edema could be greatly relieved in Treatment Group measured by CRT (t = 2.571, p = 0.007) while the difference was of no statistical significance in Control Group (t = 1.016, p = 0.070). RCT were remarkably shortened in both groups (Control Group: t = 43.83, p = 0.000; Treatment Group: t = 27.34, p = 0.000), and when compared with Control group, the changes in Treatment Group were more significant (p < 0.05). Conclusion: SS injection could effectively improve the therapeutic effect in patients with non-ischemic retinal vein occlusion.
Highlights
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathyHow to cite this paper: Lu, B.W. and Wu, X.W. (2015) Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion
Patients were excluded from the study if they had undergone any other treatment for RVO within 3 months, such as laser therapy or intravitreal injections
Sixty-two patients were randomized into Control Group and Treatment Group
Summary
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathyHow to cite this paper: Lu, B.W. and Wu, X.W. (2015) Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion. Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy. How to cite this paper: Lu, B.W. and Wu, X.W. (2015) Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion. W. Wu with significant morbidity, including branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) as well as their ischemic and non-ischemic subtypes [1]. Major causes of vision loss include macular edema and neovascularization with secondary vitreous hemorrhage and/or neovascular glaucoma [2]. Effective treatment options for RVO were limited, including grid laser photocoagulation, intravitreal injections of triamcindion acetonide and intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
